Endo Pharmaceuticals Holdings Inc.

Purdue Frederick Laboratories, Inc. and Euro-Celtique filed charges against the drug company claiming its oxycodone extended release generic version of OxyContin tablets infringed Purdue's U.S. patent. Endo launched its oxycodone extended release products on June 7, 2005 in response to a decision of the United States Court of Appeals for the Federal Circuit declaring Purdue's patents unenforceable. The Federal Circuit later reconsidered that decision and sent the case back to the United States District Court for the Southern District of New York for further consideration. Under the terms of the settlement, Endo will be allowed to continue selling oxycodone extended-release products until December 31, 2006. (Aug-28-06) [YAHOO BUSINESS]

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.